Hurwitz JT, Grizzle AJ, Tyler CS, Zapata LV, Malone DC. Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients. J Manag Care Spec Pharm. 2021;27:948–60.
Google Scholar
Nobakht E, Jagadeesan M, Paul R, Bromberg J, Dadgar S. Precision medicine in kidney transplantation: just hype or a realistic hope? Transplant Direct. 2021;7:650–64.
Google Scholar
Zaza G, Granata S, Tomei P, Dalla Gassa A, Lupo A. Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in “omics” medicine. Int J Mol Sci. 2015;16:4281–305.
Google Scholar
Arnol M, Naumovic R, Dimitrov EP, Racki S, Bucsa CA, Covic A, et al. Immunosuppressive regimens following kidney transplantation in five European countries: the observational RECORD study. Transplantation Reports. 2020;5:100061–672.
Google Scholar
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117–S314.
Google Scholar
Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87:721–6.
Google Scholar
van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002;48:1668–71.
Google Scholar
Arnol M, Smrkolj T, Avsec D, Gadžijev A, Kneževič I. An increase in kidney transplantation procedures from deceased donors during the COVID-19 epidemic in Slovenia. Transpl Int. 2020;33:1562–4. https://doi.org/10.1111/tri.13715
Google Scholar
Kandus A, Buturović Ponikvar J, Mlinšek G, Oblak M, Arnol M. Kidney Transplantation in Slovenia From 1970 to 2015. Ther Apher Dial. 2016;20:229–33.
Google Scholar
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomized crossover implementation study. Lancet. 2023;401:347–56.
Google Scholar
van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther. 2017;101:341–58.
Google Scholar
Gordois AL, Toth PP, Quek RG, Proudfoot EM, Paoli CJ, Gandra SR. Productivity losses associated with cardiovascular disease: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2016;16:759–69.
Google Scholar
Willan AR, Briggs A Statistical analysis of cost‐effectiveness data. 1st ed., John Wiley & Sons Ltd, Canada, 2006.
Rancic N, Dragojevic-Simic V, Vavic N, Kovacevic A, Segrt Z, Djordjevic N. Economic evaluation of pharmacogenetic tests in patients subjected to renal transplantation: a review of literature. Front Public Health. 2016;4:189–97.
Google Scholar
Chung R, Howard K, Craig JC, Chapman JR, Turner R, Wong G. Economic evaluations in kidney transplantation: frequency, characteristics, and quality-a systematic review. Transplantation. 2014;97:1027–33.
Google Scholar
Fragoulakis V, Koufaki MI, Joefield-Roka C, Sunder-Plassmann G, Mitropoulou C. Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study. Pharmacogenomics J. 2024;24:10–16.
Google Scholar
Morris SA, Alsaidi AT, Verbyla A, Cruz A, Macfarlane C, Bauer J, et al. Cost effectiveness of pharmacogenetic testing for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines: a systematic review. Clin Pharmacol Ther. 2022;112:1318–28.
Google Scholar
Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017;17:395–402.
Google Scholar
Stack AG, Yermak D, Roche DG, Ferguson JP, Elsayed M, Mohammed W, et al. Differential impact of smoking on mortality and kidney transplantation among adult Men and Women undergoing dialysis. BMC Nephrol. 2016;17:95–107.
Google Scholar
Weinrauch LA, Claggett B, Liu J, Finn PV, Weir MR, Weiner DE, et al. Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial. Int J Nephrol Renovasc Dis. 2018;11:155–64.
Google Scholar
James A, Mannon RB. The cost of transplant immunosuppressant therapy: is this sustainable? Curr Transplant Rep. 2015;2:113–21.
Google Scholar
Percy C, Hassoun Z, Mourad M, De Meyer M, Beguin C, Jadoul M, et al. Impact of acute infection requiring hospitalization on tacrolimus blood levels in kidney transplant recipients. Transplant Proc. 2017;49:2065–9.
Google Scholar
Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, et al. A European spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics. PLoS One. 2016;11:e0162866.
Google Scholar
